Introduction
============

The first component of complement, C1, is a multimolecular complex comprising of C1q and a Ca^2+^-dependent tetramer, C1r~2~--C1s~2.~ The role of C1q within this complex is to serve as a recognition signal -- a signal that is readily translated into a highly specific and orderly intramolecular rearrangement resulting in a sequential proteolytic activation -- first of C1r and then of C1s -- thereby triggering activation of the classical pathway (Cooper, [@B19]; Schumaker et al., [@B94]; Arlaud et al., [@B2]). However, the role of C1q is not restricted to recognition of immune complexes or other molecules that activate the classical pathway. Evidence accumulated to date clearly demonstrates that C1q is a key player in a rapidly expanding list of pathophysiological conditions which include: trophoblast invasion and placental development (Agostinis et al., [@B1]), onset of preeclampsia (Singh et al., [@B99]), regulation of autoimmune diseases such systemic lupus erythematosus (SLE; Walport et al., [@B114]) and activation of the tumor suppressor molecule WW-domain containing oxydoreductase, which plays a critical role in the pathogenesis of prostate cancer (Hong et al., [@B42]).

Unlike most of the complement proteins, which by and large are synthesized in the liver, C1q is synthesized extrahepatically by a wide range of cell types including monocytes/macrophages (Bensa et al., [@B4]; Loos, [@B65]; Tenner and Volkin, [@B109]; Kolosov et al., [@B60]; Armbrust et al., [@B3]), epithelial cells (Colten, [@B18]) mesenchymal cells (Morris et al., [@B74]), dendritic cells (Vegh et al., [@B112]; Castellano et al., [@B15]), trophoblasts (Bulla et al., [@B12]; Agostinis et al., [@B1]), microglial cells (Lynch et al., [@B67]; Farber et al., [@B21]), fibroblasts (Reid and Solomon, [@B89]; Skok et al., [@B100]; Gulati et al., [@B36]), and endothelial cells (Bulla et al., [@B12]; Bossi et al., [@B9]). The synthesized molecule in turn, is either transiently expressed as a cell membrane associated molecular ligand (mC1q; Loos, [@B65]), or secreted into the pericellular milieu where it can modulate cell-specific biological responses in a manner that involves an autocrine and/or paracrine signaling through cell surface receptors and their signaling partners (Menzies et al., [@B71]). The diversity of immunological functions mediated by C1q could perhaps be explained by having a unique structural feature: a collagen-like domain (cC1q) and a globular heads domain (gC1q) present in the same protein. This paper will shed some light into the evolution and structural basis of C1q function and highlight some of its emerging novel functions.

Structure of Human C1q
======================

*Human C1q* (460 kDa) is a collagen-like, structurally complex, hexameric glycoprotein, which associates with the Ca^2+^-dependent C1r~2~--C1s~2~ tetramer (360 kDa) to form the pentameric C1, the first component of the serum complement system (Calcott and Müller-Eberhard, [@B13]; Reid and Thompson, [@B90]; Reid, [@B87]). It is composed of six globular "*heads*" linked via six collagen-like "*stalks*" to a fibril-like central region (Shelton et al., [@B97]; Svehag et al., [@B104]; Knobel et al., [@B57]; Brodsky-Doyle et al., [@B11]; Sellar et al., [@B95]). The C1q molecule (Figure [1](#F1){ref-type="fig"}), consists of 3 remarkably similar but distinct polypeptide chains, A, B, and C, each of which occurs 6 times in the molecule to give rise to a total of 18 chains (6A, 6B, 6C; Reid, [@B87]). The three chains are the product of three distinct genes, which are aligned 5′ ⇒ 3′, in the same orientation, in the order A--C--B on a 24-kb stretch of DNA on chromosome 1p (Reid, [@B86]; Sellar et al., [@B95]). Each polypeptide chain (A = 28 kDa, B = 25 kDa, C = 24 kDa) consists of 81 amino acid-long collagen-like *N*-terminal "*stalk*" and a *C*-terminal, globular "*head*" of 136 amino acids (Reid, [@B87]). The chains are arranged to form 6 triple helical strands, three peptide chains, A, B, and C, forming one strand (Figure [1](#F1){ref-type="fig"}). In each strand, the triple helix is formed between the *N*-terminal collagen-like sequences of the three chains while the globular "*head*" is formed from the *C*-terminal portion of these chains (Sellar et al., [@B95]; Kishore and Reid, [@B54]). Chains A and B are disulfide-linked within a given strand through formation of disulfide bridges between the half-cysteine residues located at A-4 and B-4, whereas the C chain forms a disulfide bond with the C chain of the next strand through cysteine residues found at position C-4 (Reid, [@B87]). Thus, the two disulfide-linked strands form a doublet, and three doublets are linked by non-covalent forces to give C1q its signature electron microscopic structure resembling a bouquet of tulips (Shelton et al., [@B97]; Brodsky-Doyle et al., [@B11]; Figure [1](#F1){ref-type="fig"}). Approximately 8% (w/w) of human C1q is carbohydrate, which is in the form of glucosylgalactosyl disaccharide units linked to hydroxylysine residues in the cC1q domain, and six asparagine-linked sugar chains located in the gC1q domain (Yonemasu et al., [@B116]; Calcott and Müller-Eberhard, [@B13]; Reid et al., [@B88]). The two types of sugars in turn account for approximately 69 and 31% of the total carbohydrate respectively (Mizuochi et al., [@B72]; Shinkai and Yonemasu, [@B98]; Reid, [@B87]).

![**Schematic model of the subunit structure and assembly of intact of C1q**. Three similar chains -- A, B, and C -- are assembled to form disulfide-linked A--B and C--C dimers. One strand of the molecule consists of an A--B dimer non-covalently linked to a C chain forming (A--B--C). The C chain of one strand is then disulfide-linked to the C chain of a neighboring strand to give an A--B C--C B--A doublet and three such doublets are linked by non-covalent forces giving C1q its final signature "bouquet-like" structure. The length of each chain as well as the length of the gC1q and cC1q domains (for brevity, g- or c-domain) is given in parenthesis. (The figure was adapted from Reid, [@B87]).](fimmu-03-00052-g001){#F1}

From a structure--function point of view, the C1q molecule contains two very well defined major functional domains through which it enters into a wide range of molecular interactions. These domains are known as the *collagen-like domain (cC1q),* and the *globular* "*heads*" *domain (gC1q)*. Of these, the gC1q domain, which recognizes a wide range of molecular patterns including modified-self and non-self antigens, is considered to be key to the versatility of C1q function (Gaboriaud et al., [@B24]). The two domains of C1q can be purified separately after the intact C1q molecule is first subjected to either peptic digestion at pH 4.45, or collagenase digestion at near neutral pH 7.4 (Knobel et al., [@B56]). The respective purified heterotrimeric domains can then be used in functional studies, although the affinity of the individual trimeric gC1q domain is likely to be several-fold less than that of the intact C1q because of the multivalency of the latter (Tacnet et al., [@B106]). Evidence accumulated to date convincingly shows that the two domains of C1q participate in a multiplicity of immunological functions by serving as a binding sites for a long list of pathogen-associated molecular patterns (PAMPs) as well as danger associated molecular patterns (DAMPs). These include viral proteins such as gp41 (Ebenbichler et al., [@B20]), acute phase proteins such as C-reactive protein (Jiang et al., [@B48]; Gewurz et al., [@B28]), bacterial and mitochondrial membranes (Gewurz et al., [@B28]), DNA (Jiang et al., [@B48]), as well as β-amyloid peptide (Jiang et al., [@B47]; Tacnet-Delorme et al., [@B107]). The gC1q domain has a heterotrimeric structure composed of the C-terminal halves of each of the three chains A, B, and C, and each of these heterotrimeric structures are postulated to function independently (Kishore and Reid, [@B54], [@B55]). Because of the availability of recombinant forms of each of the globular heads (gh) or modules, it has now been possible to purify the individual modules (ghA, ghB, and ghC) as recombinant proteins and study their individual roles in ligand binding and biological function (Kishore et al., [@B52]; Ghai et al., [@B29]). Indeed, mutational studies using ghA, ghB, and ghC modules have identified the gh residues involved in recognition of IgG and IgM (Kojouharova et al., [@B58]; Gadjeva et al., [@B26]). In addition to recognition of self and non-self antigens, C1q can enter into a vast array of interactions by binding to cell surface molecules either via its cC1q or gC1q domain. C1q receptors mediate a plethora of immunologic functions including phagocytosis, and clearance of apoptotic cells (Bobak et al., [@B6]; Nauta et al., [@B75]; Païdassi et al., [@B81]).

Although the list of cell surface or cell associated molecules recognized by C1q is increasing, there are at least two well characterized and ubiquitously distributed cell surface molecules -- known respectively as cC1qR and gC1qR -- that recognize the two domains of C1q (Ghebrehiwet and Peerschke, [@B33]). Although each of these molecules lacks a consensus sequence motif for a traditional transmembrane segment, the lack of direct conduit to intracellular signaling elements is circumvented by the formation of a docking/signaling complex with transmembrane proteins. This partnership in turn is dictated by the specific biological response to be induced (Ghebrehiwet et al., [@B32]; Ghebrehiwet and Peerschke, [@B33]). Each of these receptors is a multiligand binding protein capable of inducing a wide range of cellular functions (Ghebrehiwet and Peerschke, [@B33]). More importantly, binding of C1q to cell surfaces via either receptor induces a plethora of biological functions that play a critical role in innate and adaptive immunity, inflammation, infection, and cancer (Ghebrehiwet et al., [@B32]).

The C1q Family of Proteins
==========================

From data available to date, it has become clear that the unusual feature of having a *collagen-like* and *globular region* in the same protein is not unique to C1q. Instead, the data show that C1q belongs to a long list of oligomeric proteins that are structurally and functionally similar. These proteins, whose members include: *mannan-binding lectin* (*MBL*), *lung surfactant protein A* (*SP-A*), SP-D, *collectin-43* (*CL-43*), collectin-46 (CL-46), and *bovine conglutinin* (Malhotra et al., [@B68]) are collectively known as collectins (*col*lagen containing *lectins*) by virtue of having collagen-like sequences contiguous with non-collagen-like stretches (Hoppe and Reid, [@B43]). Collectins are calcium dependent molecules and belong to a group III of the family of lectins containing C-type carbohydrate recognition domains (CRD; Lu et al., [@B66]; Hakansson and Reid, [@B37]). Their genes characteristically contain a small exon encoding a 36 amino acid-long neck region, which links the collagen domain with the CRD. The CRD in turn, is responsible for recognition of glycoconjugates containing mannose and fucose on microorganisms but *not* on self-proteins, resulting in enhanced clearance of pathogenic microorganisms (Hakansson and Reid, [@B37]). Unlike the collectins however, C1q does not possess a consensus domain for CRD, but it shares another common feature with the collectins in that it possesses galactose--glucose disaccharides attached to the collagenous regions of each protein (Mizuochi et al., [@B72]; Reid, [@B85]; Shinkai and Yonemasu, [@B98]). Despite lacking a CRD domain however, recent data suggest that C1q also has lectin-like activity suggesting that carbohydrates -- especially those on pathogens and apoptotic cells -- may provide additional binding targets where the binding of C1q is critical for removal of self waste (Païdassi et al., [@B80]).

In addition to the collectins, several other molecules, which are structurally similar to C1q, have also been described. One of these is, adipocyte complement-related protein of 30 kDa (ACRP30) or adiponectin (Scherer et al., [@B93]; Hu et al., [@B46]; Berg et al., [@B5]; Wong et al., [@B115]). ACRP30 or adiponectin, is secreted exclusively from fat cells and implicated in energy homeostasis and obesity as well as enhancement of hepatic insulin action (Berg et al., [@B5]; Wong et al., [@B115]). It is a protein of 247 amino acids consisting of an *N*-terminal collagen-like domain and a *C*-terminal globular domain (Scherer et al., [@B93]; Berg et al., [@B5]). The globular domain shares a significant homology to the globular domains of type VIII and X collagens as well as subunits of C1q. More intriguing however is the fact that the crystal structure of a homotrimeric fragment from ACRP30 revealed an unexpected homology to the tumor necrosis factor (TNF) family of proteins. Because of identical folding topologies, key residue conservations, and similarity of trimer interfaces and intron positions, these studies have firmly established an evolutionary link between the TNF-α and the C1q family of proteins suggesting that TNF arose by divergence from an ancestral recognition molecule of the innate immune system (Shapiro and Scherer, [@B96]). The evolutionary connection between C1q-like proteins and TNF-α, which control many aspects of *inflammation*, adaptive immunity, *apoptosis*, and energy homeostasis, not only sheds insight into the shared diverse functions of this family of proteins (Shapiro and Scherer, [@B96]), but also explains why C1q has retained some of its "*cytokine-like*" activities. Structurally, the C1q/TNF family of proteins contains the same compact "jellyroll" β fold, usually organized as trimers but with diverse functions ranging from cytokine activity (TNF-α), regulation of metabolism (ACRP30), connective tissue organization (collagen type VIII and X), cellular activation (CD40L), and innate immunity (C1q; Kishore et al., [@B53], [@B51]; Gaboriaud et al., [@B25]). More recently, the crystal structure of the gC1q domain of C1q was solved and the structure reveals a compact, almost spherical heterotrimeric assembly held together mainly by non-polar interactions, with a Ca^2+^ ion bond at the top of the molecule (Gaboriaud et al., [@B24]). More importantly, the structural studies revealed that the heterotrimeric assembly of the gC1q domain appears to have unique features that allow its versatility (Gaboriaud et al., [@B24]). Other molecules in which the "gC1q domains" are found at the C-terminal end include: precerebellin (Kavety et al., [@B49]), multimerin (Hayward et al., [@B38]), and types VIII and X collagens (Bogin et al., [@B7]). Therefore, despite its similarities with the collectins, the structural folds of the gC1q domain, which are more similar to the TNF than to the CRD region of the collectins -- make C1q more related to the TNF family of proteins (Kishore et al., [@B51]).

The significance of a particular human protein is sometimes underscored by the fact that pathogenic microorganisms specifically mimic its functional domain or antigenic determinant for the purpose of immune evasion and thus enhance their survival. For example, the three-dimensional structure of the major surface protein of *Bacillus anthracis* spore surface protein, bacillus collagen-like protein of anthracis (BclA) reveals remarkable similarity to C1q -- although there is only low sequence identity between the two proteins (Sylvestre et al., [@B105]; Rety et al., [@B91]). Furthermore, both BclA and C1q have been shown to bind to lung alveolar surfactant component-SP-C, suggesting that both recognize common targets in the alveolar component (Rety et al., [@B91]). This molecular mimicry in turn, underscores not only the functional relevance of the gC1q domain, but also pathogenic microorganisms mimic this signature domain in order to get access into host cells. The exosporium of *B. cereus,* which belongs to the same genus of spore-forming aerobic bacteria as *B. anthracis*, contains a binding site for gC1qR. Although the nature of the *B. cereus* molecule has not been as yet identified, the fact that it recognizes gC1qR on cells for the initial spore attachment and entry suggests that this molecule may also contain a gC1q-like domain (Ghebrehiwet et al., [@B35]).

The Diverse Biological Functions of C1q
=======================================

Although for many years, the traditionally accepted role of C1q is the recognition of immune complexes and activation of the classical pathway, there is an ever-growing body of evidence, which suggests that C1q is a major sensor of DAMPs and PAMPS and plays a critical role in inflammation as well as innate and adaptive immunity (Figure [2](#F2){ref-type="fig"}) (Kojouharova et al., [@B59]; Sontheimer et al., [@B102]; Ghai et al., [@B29]; Gadjeva et al., [@B26]; Païdassi et al., [@B80]; Hosszu et al., [@B45]). In addition, C1q induces a plethora of immunologic functions by interaction with distinct cell surface molecules, which recognize either, its gC1q or cC1q domain (Ghebrehiwet and Peerschke, [@B33]). These cell surface molecules include cC1qR or calreticulin (CR), gC1qR (Malhotra et al., [@B68]; Ghebrehiwet and Peerschke, [@B33]) CD93 (Nepomuceno et al., [@B77]; Steinberger et al., [@B103]), as well as other associated adapter molecules such as CD91 (Ogden et al., [@B79]; Gardai et al., [@B27]), CD44, DC-SIGN, and β1 integrin (Feng et al., [@B22]; Menzies et al., [@B71]). Interaction of C1q with cell surface molecules, induces a wide range of biological responses including stimulation of leukocyte oxidative response (Tenner and Cooper, [@B108]), phagocytosis (Bobak et al., [@B6]), suppression of B and T cell proliferation (Ghebrehiwet et al., [@B31]), fibroblast and endothelial cell adhesion (Bordin et al., [@B8]; Chen et al., [@B17]; Feng et al., [@B22]), trophoblast cell migration (Agostinis et al., [@B1]), regulation of dendritic cells (Castellano et al., [@B15],[@B16]; Hosszu et al., [@B45]), angiogenesis (Bossi et al., [@B9]), and chemotaxis of eosinophils, mast cells, neutrophils, and dendritic cells (Ghebrehiwet et al., [@B30]; Kuna et al., [@B63]; Leigh et al., [@B64]; Vegh et al., [@B113]). Another interesting aspect of the C1qRs, is that both are released into the pericellular milieu, by proliferating, activated, or proinflammatory cells. Because both are capable of activating the classical pathway, it is believed that the secreted molecules may exacerbate or trigger the local inflammatory process. The binding site for gC1qR on C1q has been shown to be on the A-chain of C1q (Ghebrehiwet et al., [@B32]), which is the same or overlapping site to a putative IgG site (Marques et al., [@B69]).

![**The emerging and reemerging functions of C1q**. The figure is intended not to a representative of the plethora of C1q-mediated functions, but rather is intended to highlight the growing list of emerging and reemerging non-traditional functions of C1q. For a more or less complete list of C1q functions see recent paper by Nayak et al. ([@B76]).](fimmu-03-00052-g002){#F2}

C1q Deficiency and Autoimmunity
===============================

The significance of C1q in health and disease is further underscored by the fact that deficiency in C1q leads to a plethora of diseases including recurrent infections, otitis media, meningitis, pneumonia (Nishino et al., [@B78]; Komatsu et al., [@B61]) as well as autoimmune diseases, a prototype of which is SLE. In fact, deficiency of C1q is considered to be a strong susceptibility factor for SLE as evidenced by the fact that almost all (≥92%) of the known patients with C1q deficiency have developed the disease (Botto et al., [@B10]; Walport et al., [@B114]; Pickering et al., [@B84]). The significance of C1q in SLE is further substantiated by the finding that, peripheral blood monocytes from SLE donors, who are not C1q deficient, have a significantly impaired ability to upregulate C1q synthesis both at the mRNA and protein levels, when compared to their healthy counterparts (Moosig et al., [@B73]). Furthermore, previous studies have shown SLE patients to synthesize high levels of a non-functional, low molecular weight form of C1q, that run with an apparent molecular weight of 150 kDa by gel filtration (Hoekzema et al., [@B41]). This non-functional form of C1q is characterized by having an abnormal A--C disulfide bonding instead of the normal pattern, which is A--B and C--C (Hoekzema et al., [@B41], [@B40], [@B39]). Although this form of C1q retains affinity for the C1r~2~C1s~2~-complex, it does not bind to the Fc in IgG aggregates (Martin and Loos, [@B70]). Because cultured monocytes from normal individuals can synthesize both the dysfunctional as well as the normal forms of C1q, it is hypothesized that in disease states such as SLE, a condition may exist which favors a disproportionate concentration of dysfunctional C1q, especially since the normal C1q would be depleted due to complement activation (Hoekzema et al., [@B41]). Although the molecular underpinnings are still being worked out, two hypotheses have been put forth to explain the role of C1q in SLE. The *first* deals with the role of C1q in removal of apoptotic waste. Removal of apoptotic cells and cellular debris is essential for maintenance of tissue homeostasis, organogenesis, remodeling, development, and maintenance of the immune system, protection against neoplasia, and resolution of inflammation. The mechanism of this removal involves the recognition of the apoptotic cell surface and initiation of phagocytic uptake by macrophages and dendritic cells. C1q, has been shown to play a major role both in the recognition and removal of apoptotic cells (Casciola-Rosen et al., [@B14]; Korb and Ahearn, [@B62]) through interaction with C1q receptors expressed both on the phagocytic cell (e.g., cC1qR/CD91; Ogden et al., [@B79]; Vandivier et al., [@B111]), and the apoptotic cell (phosphatidylserine, DNA, and possibly gC1qR; Païdassi et al., [@B80]). This in turn implies that defective clearance of immune complexes and apoptotic cells, leads to immune recognition of hidden epitopes -- a critical immunopathogenic event leading to the development of SLE, the prototype autoimmune disease. Indeed, C1q directly and specifically binds to antigens expressed early on the surface of apoptotic cells through its gC1q domain (Korb and Ahearn, [@B62]; Païdassi et al., [@B80]) and the common autoantigens targeted in SLE, such as phosphatidylserine and DNA are found in high concentrations on the surface of apoptotic cells (Casciola-Rosen et al., [@B14]). However, while its role in removal of apoptotic debris is clearly important, there are a number of redundant pathways involved in the removal of self waste, thus making the role of C1q not as critical (Ghebrehiwet and Peerschke, [@B34]). The *second* hypothesis stipulates that autoimmunity arising from the absence or inefficient C1q function, especially at local sites, reflects an important role in maintaining tolerance (Ghebrehiwet and Peerschke, [@B34]; Hosszu et al., [@B44], [@B45]). Thus, while C1q could provide active protection from autoimmunity by silencing or regulating autoreactive immune cells, its absence or defective secretion could lead to a loss of peripheral tolerance as a sum total of impaired apoptotic cell clearance and negative signaling (Hosszu et al., [@B45]). Inherent in this postulate is the notion that the unique structure of C1q, which allows it to interact with its receptors via either its cC1q or gC1q domain, may control the transition from the monocyte state (innate immunity) toward the professional antigen presenting cell (APCs) state (adaptive immunity). Therefore the recent observation showing that C1q functions as a "*molecular switch*" during the narrow window of monocyte to DC transition (Hosszu et al., [@B44], [@B45]), not only explains why C1q is primarily synthesized by potent APCs, but also underscores why its absence can impair antigen uptake and tolerance.

Local Synthesis and Function of C1q
===================================

As described above, most inflammatory cells such as those found in atherosclerotic plaques (Peerschke et al., [@B83]) or cells that undergo phenotypic differentiation or proliferation are known to express and/or secrete C1q (Vegh et al., [@B112]; Bulla et al., [@B12]; Hosszu et al., [@B44]). The emerging postulate is therefore, that locally secreted C1q modulates cellular function (s) by an autocrine and/or paracrine signaling mechanism. For example, fetal trophoblast cells invading the decidua in the early stages of pregnancy not only actively synthesize and express C1q on their surface, but this C1q is actively involved in promoting trophoblast invasion of the decidua (Agostinis et al., [@B1]). This in turn is mediated by two cell surface receptors -- gC1qR and α~4~β~1~ integrin, which promote trophoblast adhesion and migration through the activation of ERK1/2 MAPKs (Agostinis et al., [@B1]). In support of this is the finding that C1q−/− mice manifested increased frequency of fetal resorption, reduced fetal weight, and smaller litter size when compared to their wild-type counterparts suggesting that defective local production of C1q may be involved in pregnancy disorders such as preeclampsia (Agostinis et al., [@B1]). The significance of C1q in pregnancy disorders is further supported by an independent study, which showed that pregnant C1q−/− mice express the key features of human preeclampsia that correlate with increased fetal death (Singh et al., [@B99]). Treatment of C1q−/− mice with pravastatin restored trophoblast invasiveness, placental blood flow, and angiogenic balance and, thus, prevented the onset of preeclampsia (Singh et al., [@B99]). It is also important to note within this context, the results of recent studies, which showed that *in vivo*, C1q induces angiogenesis and promotes wound healing. This in turn identifies not only a novel role but also identifies C1q as a potential pro-angiogenic molecule for the treatment of wounds and chronic ulcers (Bossi et al., [@B9]).

The Emerging Role of C1q in Carcinogenesis
==========================================

Another emerging role of C1q is in the regulation of cancer cell survival and progression. Recent studies have shown that C1q, which is expressed on basal and epithelial cells of prostate tissues, sustains the activation of the tumor suppressor WOX1 (WW-domain containing oxydoreductase), which is needed for blocking cancer cell proliferation. This suggests that C1q may induce apoptosis of prostate cancer cells by activating WOX1 and destabilizing cell adhesion. Conversely, downregulation of C1q was found to enhance prostate hyperplasia and cancerous formation due to failure of WOX1 activation (Hong et al., [@B42]). More importantly, although C1q is expressed in the normal prostate, it is significantly reduced in benign prostatic hyperplasia and prostate cancer tissues (Hong et al., [@B42]). Therefore, the C1q/WOX1-induced death of cancer cells could have a universal implication in cancer, as long as C1q and WOX1 are present in both the extracellular and intracellular milieu, and are sufficient in activating the apoptotic cascade (Hong et al., [@B42]). However, since the autocrine or paracrine signaling effect of locally expressed C1q is most likely going to be in concert with its cell surface receptors and signaling partners, it is important to note that both cC1qR/calreticulin (cC1qR/CRT) and gC1qR have also been implicated in carcinogenesis, albeit their roles seem to be rather divergent. Whereas cC1qR/CRT is reported to have tumor suppressive effect, gC1qR appears to be requisite for tumor cell progression and metastasis. For example, when Epstein--Barr virus (EBV)-immortalized B lymphocytes were injected into nude mice, they were found to reproducibly inhibit tumor growth (Tosato et al., [@B110]). This anti-tumor activity, which is released by the lymphoblastic cells, was later identified to be a fragment of cC1qR/CRT corresponding to the N-terminal residues 1--180. Subsequently, recombinant protein corresponding to this N-terminal fragment was found to inhibit endothelial cell proliferation *in vitro* and angiogenesis *in vivo* (Tosato et al., [@B110]). The inhibition of endothelial cell proliferation was due to direct binding of the cC1qR/CRT fragment to the extracellular matrix protein, laminin thereby interfering with endothelial cell attachment. Further studies showed that subcutaneous inoculation of recombinant CRT fragment into nude mice not only prevented the development of subcutaneous tumors, but also inhibited the growth of established ones (Tosato et al., [@B110]). Since the collagen tail of C1q (cC1q) binds to the N-terminal half of cC1qR/CRT, which contains several short (7--10 amino acids) CH2-like motifs (ExKxKx) similar to the C1q binding motif found in the CH2 domain of IgG (Sontheimer et al., [@B101]), these C1q binding regions of cC1qR/CRT have the potential to be developed into therapeutic modalities.

The receptor for the ghs of C1q, gC1qR, on the other hand, may have functions that enhance tumor growth and tumor progression. First, histochemical staining with anti gC1qR mAb revealed marked differential expression of gC1qR in thyroid, colon, pancreatic, gastric, esophageal, and lung adenocarcinomas compared to the non-malignant histologic counterparts. In contrast, differential expression was not observed in endometrial, renal, and prostate carcinomas (Rubinstein et al., [@B92]; Peerschke et al., [@B82]). Recent studies not only corroborated these findings, but additionally showed that cell surface expressed gC1qR is a receptor for the tumor homing peptide, LyP-1 (Fogal et al., [@B23]). Moreover, recent studies using human lung carcinoma A549 cells have shown the cell surface gC1qR to be a key regulator for lamellipodia formation and cancer metastasis via receptor tyrosine kinase activation. Furthermore, the growth factor-induced lamellipodia formation and cell migration were significantly decreased in gC1qR-depleted cells, with a concomitant blunt activation of the focal adhesion kinase and the respective receptor tyrosine kinases (Kim et al., [@B50]). These studies collectively suggest that gC1qR, which is highly upregulated on the surface of tumor cells and inflammatory cell scan serve not only as a tumor cell marker, but also can be a target for therapeutic intervention (Peerschke et al., [@B82]).

Concluding Remarks
==================

Because of the incredible number of reports that have come out in the past 20 years, it is not possible to list all the functions in which C1q is involved. Therefore, while touching on some of the well known functions of C1q, this paper underscores the role of C1q in novel and emerging areas of diseases (e.g., preeclampsia, cancer, and wound healing) in which either the soluble form or the membrane associated form of C1q appear to be intimately involved. The chimeric structure of C1q -- containing two functional domains -- together with the fact that it is synthesized by a wide range of proinflammatory cell types makes it likely that it is a potent orchestrator of molecular pathways involved not only in innate and adaptive immunity, but also in a wide range of inflammatory diseases including cancer. The heterotrimeric gC1q domain of C1q is also revealing itself as a powerful pattern recognition domain with the ability to sense a broad range of ligands -- including a number of altered self-motifs and pathogen-associated molecular ligands -- each of which will likely trigger a multiplicity of immunologic functions, which are either beneficial or deleterious to the host. More than ever, the availability of recombinant forms of the heterotrimeric trimeric gC1q domains will undoubtedly help us gain insight into the mechanism of interaction between C1q and the vast array of molecular patterns. The best is yet to come.
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